JP2016520514A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520514A5 JP2016520514A5 JP2016501063A JP2016501063A JP2016520514A5 JP 2016520514 A5 JP2016520514 A5 JP 2016520514A5 JP 2016501063 A JP2016501063 A JP 2016501063A JP 2016501063 A JP2016501063 A JP 2016501063A JP 2016520514 A5 JP2016520514 A5 JP 2016520514A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- humanized
- antigen
- binding construct
- lcdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780286P | 2013-03-13 | 2013-03-13 | |
| US61/780,286 | 2013-03-13 | ||
| PCT/US2014/022782 WO2014164553A1 (en) | 2013-03-13 | 2014-03-10 | Antigen binding constructs to cd8 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018230270A Division JP6856611B2 (ja) | 2013-03-13 | 2018-12-07 | Ｃｄ８に対する抗原結合性構築物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520514A JP2016520514A (ja) | 2016-07-14 |
| JP2016520514A5 true JP2016520514A5 (enExample) | 2017-04-13 |
| JP6815196B2 JP6815196B2 (ja) | 2021-01-20 |
Family
ID=51527868
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501063A Active JP6815196B2 (ja) | 2013-03-13 | 2014-03-10 | Ｃｄ８に対する抗原結合性構築物 |
| JP2018230270A Active JP6856611B2 (ja) | 2013-03-13 | 2018-12-07 | Ｃｄ８に対する抗原結合性構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018230270A Active JP6856611B2 (ja) | 2013-03-13 | 2018-12-07 | Ｃｄ８に対する抗原結合性構築物 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US20140271462A1 (enExample) |
| EP (3) | EP3889182B1 (enExample) |
| JP (2) | JP6815196B2 (enExample) |
| KR (2) | KR102353885B1 (enExample) |
| CN (2) | CN113045660B (enExample) |
| AU (2) | AU2014249243C1 (enExample) |
| CA (1) | CA2904969C (enExample) |
| WO (1) | WO2014164553A1 (enExample) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2806252C (en) | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Antibodies with modified isoelectric points |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| HRP20191865T1 (hr) | 2013-01-14 | 2020-01-10 | Xencor, Inc. | Novi heterodimerni proteini |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| CN113045660B (zh) | 2013-03-13 | 2023-09-01 | 伊麦吉纳博公司 | 与cd8的抗原结合构建体 |
| CA3093606A1 (en) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins for induction of t cells |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| EP3954713A3 (en) | 2014-03-28 | 2022-03-30 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| CN116333153A (zh) | 2014-11-26 | 2023-06-27 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| US20160176969A1 (en) * | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| ES3020458T3 (en) | 2015-08-07 | 2025-05-22 | Imaginab Inc | Antigen binding constructs to target molecules |
| KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| CN109476721B (zh) * | 2016-04-04 | 2022-06-28 | 英蒂分子公司 | Cd8-特异性捕获剂、组合物及使用和制备方法 |
| SG11201808751SA (en) | 2016-04-08 | 2018-11-29 | Adaptimmune Ltd | T cell receptors |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| IL263542B2 (en) | 2016-06-14 | 2024-10-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
| KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
| WO2018007314A1 (en) * | 2016-07-04 | 2018-01-11 | F. Hoffmann-La Roche Ag | Novel antibody format |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN110214148A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白 |
| EP3548515A1 (en) | 2016-12-01 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| KR102880156B1 (ko) * | 2017-07-24 | 2025-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 항cd8 항체 및 이의 용도 |
| CN119285770A (zh) | 2017-08-09 | 2025-01-10 | 奥里尼斯生物科学有限公司 | Pd-1和pd-l1结合剂 |
| CN117924493A (zh) | 2017-08-09 | 2024-04-26 | 奥里尼斯生物科学有限公司 | Clec9a结合剂及其用途 |
| JP7347899B2 (ja) | 2017-08-09 | 2023-09-20 | オリオンズ バイオサイエンス インコーポレイテッド | Ｃｄ８結合物質 |
| CA3070297A1 (en) * | 2017-08-11 | 2019-02-14 | Genentech, Inc. | Anti-cd8 antibodies and uses thereof |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| MX2020006322A (es) | 2017-12-19 | 2020-09-18 | Xencor Inc | Proteinas de fusion il-2 fc modificadas. |
| MX2020007024A (es) | 2018-01-03 | 2020-10-28 | Palleon Pharmaceuticals Inc | Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas. |
| MX2020008208A (es) | 2018-02-05 | 2020-11-09 | Orionis Biosciences Inc | Agentes de unión a fibroblastos y uso de estos. |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| AU2019256539A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
| EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| AU2019282248A1 (en) | 2018-06-08 | 2021-01-07 | Imaginab, Inc. | Antigen binding constructs to CD4 |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| AU2019351264A1 (en) | 2018-09-28 | 2021-04-29 | Imaginab, Inc. | CD8 imaging constructs and methods of use thereof |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| AU2020232605A1 (en) | 2019-03-01 | 2021-10-21 | Xencor, Inc. | Heterodimeric antibodies that bind ENPP3 and CD3 |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| US20220257796A1 (en) | 2019-07-02 | 2022-08-18 | Fred Hutchinson Cancer Research Center | Recombinant ad35 vectors and related gene therapy improvements |
| US20230211024A1 (en) * | 2019-12-05 | 2023-07-06 | Imaginab, Inc. | Methods of imaging using multiple imaging agents |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| US20240209089A1 (en) * | 2020-07-21 | 2024-06-27 | Suzhou Smartnuclide Biopharmaceutical Co., Ltd. | Cd8 binding polypeptide and use thereof |
| KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| MX2023008028A (es) * | 2021-01-06 | 2023-08-14 | Palleon Pharmaceuticals Inc | Anticuerpos anti-pd-l1 y proteinas de fusion de estos. |
| WO2022150731A1 (en) | 2021-01-11 | 2022-07-14 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| US11535869B2 (en) | 2021-04-08 | 2022-12-27 | Sana Biotechnology, Inc. | CD8-specific antibody constructs and compositions thereof |
| WO2023010060A2 (en) | 2021-07-27 | 2023-02-02 | Novab, Inc. | Engineered vlrb antibodies with immune effector functions |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250032618A1 (en) | 2021-11-10 | 2025-01-30 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| EP4590688A1 (en) | 2022-09-21 | 2025-07-30 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| EP4627096A1 (en) | 2022-12-02 | 2025-10-08 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| CN120917051A (zh) | 2023-03-16 | 2025-11-07 | 天劢源和有限公司(开曼) | 多特异性抗原结合蛋白及其用途 |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| AU2024275646A1 (en) * | 2023-05-24 | 2025-11-13 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
| AU2024280595A1 (en) | 2023-05-30 | 2025-09-04 | Imnotech Gmbh | Anti-cd2 single domain antibody, a pharmaceutical composition and a kit for use in the diagnosis and/or therapy of cancer |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025064435A1 (en) | 2023-09-19 | 2025-03-27 | Imaginab, Inc. | Antigen binding constructs directed to integrin αvβ6 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| EP4600270A1 (en) | 2024-02-08 | 2025-08-13 | ImnoTech GmbH | Anti-cd7 single domain antibody (sdab), a pharmaceutical composition and a kit for use in the diagnosis and/or therapy of cancer |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN118286410B (zh) * | 2024-06-06 | 2024-09-13 | 山东兴瑞生物科技有限公司 | 一种偶联CD8抗体的肿瘤mRNA疫苗的制备方法 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| US4709015A (en) | 1979-12-04 | 1987-11-24 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human suppressor T cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| ZA936260B (en) | 1992-09-09 | 1994-03-18 | Smithkline Beecham Corp | Novel antibodies for conferring passive immunity against infection by a pathogen in man |
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| EP2258726A1 (en) * | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
| EP2338915A3 (en) * | 1997-04-07 | 2011-10-12 | Genentech, Inc. | Anti-VEGF antibodies |
| DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
| US7829064B2 (en) | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
| US20040209314A1 (en) | 1999-09-06 | 2004-10-21 | Institut National De La Sante Et De La Recherche Medicale France | Means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA |
| RU2199115C2 (ru) | 2000-07-10 | 2003-02-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Способ прогноза развития инфекции и тяжелых инфекционных осложнений у больных гемобластозами на программной полихимиотерапии |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US8101157B2 (en) | 2001-10-03 | 2012-01-24 | Vanderbilt University | Ligands to radiation-induced molecules |
| US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| WO2003074567A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Internalizing anti-cd74 antibodies and methods of use |
| US20040023415A1 (en) | 2002-03-05 | 2004-02-05 | Konstantin Sokolov | Biospecific contrast agents |
| US7615355B2 (en) * | 2002-04-22 | 2009-11-10 | Georgetown University | Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration |
| US7597876B2 (en) | 2007-01-11 | 2009-10-06 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| US7993626B2 (en) | 2007-01-11 | 2011-08-09 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
| US7563433B2 (en) | 2007-01-11 | 2009-07-21 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
| CA2507080C (en) | 2002-11-27 | 2015-01-06 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactic proteins |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| EP1587550B1 (en) | 2003-01-31 | 2011-07-27 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
| CA2522380A1 (en) | 2003-03-19 | 2004-09-30 | Isogenis, Inc. | Specific inhibition of allorejection |
| US9005613B2 (en) | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
| CA2441653A1 (en) | 2003-09-19 | 2005-03-19 | William Herman | Targeted ligands |
| US7273608B2 (en) * | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| US20050281740A1 (en) | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue |
| US20080193376A1 (en) | 2004-10-28 | 2008-08-14 | The General Hospital Corporation | Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation |
| WO2006050058A2 (en) | 2004-10-28 | 2006-05-11 | The General Hospital Corporation | Methods of detection and therapy of inflamed tissues using immune modulation |
| ATE462726T1 (de) | 2005-01-07 | 2010-04-15 | Diadexus Inc | Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| WO2007112316A2 (en) | 2006-03-24 | 2007-10-04 | Morton Donald L | Mycobacterial immunotherapy for cancer treatment |
| AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
| US8709382B2 (en) | 2007-01-11 | 2014-04-29 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| US20160045626A1 (en) | 2007-01-11 | 2016-02-18 | Immunomedics, Inc. | Methods and Compositions for Improved Labeling of Targeting Peptides |
| WO2008088648A2 (en) | 2007-01-11 | 2008-07-24 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
| US8889100B2 (en) | 2007-01-11 | 2014-11-18 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| US8545809B2 (en) | 2007-01-11 | 2013-10-01 | Immunomedics, Inc. | Methods and compositions for improved 18F labeling of proteins, peptides and other molecules |
| US20150086482A1 (en) | 2007-01-11 | 2015-03-26 | Immunomedics, Inc. | Dye Conjugated Peptides for Fluorescent Imaging |
| US20090088578A1 (en) | 2007-01-19 | 2009-04-02 | Lascola Christopher D | Nuclear magnetic resonance imaging of selective small molecule drugs as contrast agents |
| WO2008127735A1 (en) | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| US20100322861A1 (en) | 2007-11-27 | 2010-12-23 | Gambhir Sanjiv S | Engineered cells, imaging report gene/probe systems, and methods of imaging |
| JP5309775B2 (ja) | 2008-08-07 | 2013-10-09 | セイコーエプソン株式会社 | 放電灯の駆動装置および駆動方法、光源装置並びに画像表示装置 |
| KR20110043786A (ko) * | 2008-08-20 | 2011-04-27 | 센토코 오르토 바이오테크 인코포레이티드 | 조작된 항-ｉｌ-13 항체, 조성물, 방법 및 용도 |
| PE20120586A1 (es) * | 2009-01-29 | 2012-06-17 | Abbott Lab | Proteinas de union a il-1 |
| DE102009030321A1 (de) | 2009-06-24 | 2011-01-05 | Siemens Aktiengesellschaft | Verfahren zur Abbildung von Tumorgewebe |
| WO2011003171A1 (en) | 2009-07-08 | 2011-01-13 | Smart Technologies Ulc | Three-dimensional widget manipulation on a multi-touch panel |
| US8772459B2 (en) * | 2009-12-02 | 2014-07-08 | Imaginab, Inc. | J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use |
| JP5789821B2 (ja) | 2009-12-04 | 2015-10-07 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | タンパク質、ペプチドおよび他の分子の改善されたｆ−１８標識化のための方法および組成物 |
| US20130137975A1 (en) | 2010-02-09 | 2013-05-30 | OSI Pharmaceuticals, LLC | Pet imaging |
| EP2556379B1 (en) | 2010-10-28 | 2014-07-09 | Avicenna Research Institute | A 38 kda form of prelp as new diagnosis and therapeutic target |
| EP2476754A1 (en) * | 2011-01-14 | 2012-07-18 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv) |
| EP2675485A4 (en) | 2011-02-15 | 2014-10-15 | Immunomedics Inc | ANTI-MUCIN ANTIBODY FOR THE EARLY RECOGNITION AND TREATMENT OF PANCREATIC CANCER |
| JP2014514314A (ja) | 2011-04-20 | 2014-06-19 | ゲンマブ エー／エス | Ｈｅｒ２およびｃｄ３に対する二重特異性抗体 |
| EP2739312B1 (en) * | 2011-08-03 | 2017-10-04 | Children's Medical Center Corporation | A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
| JP2015508903A (ja) | 2012-02-28 | 2015-03-23 | コーネル ユニヴァーシティー | 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| EP3786183A3 (en) | 2012-06-15 | 2021-06-09 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| WO2014025828A1 (en) | 2012-08-06 | 2014-02-13 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| CN113045660B (zh) | 2013-03-13 | 2023-09-01 | 伊麦吉纳博公司 | 与cd8的抗原结合构建体 |
| CN107614020A (zh) | 2015-03-18 | 2018-01-19 | 免疫生化公司 | 靶向细胞内肿瘤相关抗原的用于治疗癌症的缀合物 |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| WO2016176652A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| JP6985934B2 (ja) | 2015-04-29 | 2021-12-22 | フレッド ハッチンソン キャンサー リサーチ センター | 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用 |
| CA2985125A1 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
| US20170007727A1 (en) | 2015-07-07 | 2017-01-12 | Immunomedics, Inc. | METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES |
| ES3020458T3 (en) | 2015-08-07 | 2025-05-22 | Imaginab Inc | Antigen binding constructs to target molecules |
| EA201890729A1 (ru) | 2015-09-14 | 2018-09-28 | Элпайн Имьюн Сайнс, Инк. | Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками |
| US12048753B2 (en) | 2015-10-01 | 2024-07-30 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
| CN109476721B (zh) | 2016-04-04 | 2022-06-28 | 英蒂分子公司 | Cd8-特异性捕获剂、组合物及使用和制备方法 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| AU2017257254B2 (en) | 2016-04-27 | 2022-02-24 | Immunomedics, Inc. | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
| WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| EP3266465A1 (en) | 2016-07-06 | 2018-01-10 | Julius-Maximilians-Universität Würzburg | Immune complexes |
| WO2018053328A1 (en) | 2016-09-16 | 2018-03-22 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| JP7104703B2 (ja) | 2016-12-14 | 2022-07-21 | ヤンセン バイオテツク，インコーポレーテツド | Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン |
| US11517627B2 (en) | 2017-01-20 | 2022-12-06 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| WO2018187215A1 (en) | 2017-04-03 | 2018-10-11 | Merrimack Pharmaceuticals, Inc. | Bispecific 4-1bb agonist molecules |
| BR112019023540A2 (pt) | 2017-05-10 | 2020-05-26 | The Wistar Institute Of Anatomy And Biology | Método para gerar uma sequência de ácidos nucleicos e para tratar um sujeito, anticorpo codificado por dna estruturalmente modificado, e, composição. |
| CA3067351A1 (en) | 2017-06-15 | 2018-12-20 | Nai-Kong Cheung | Anti-l1-cam antibodies and uses thereof |
| WO2019012147A1 (en) | 2017-07-13 | 2019-01-17 | Institut Gustave-Roussy | RADIOMY-BASED IMAGING TOOL FOR MONITORING INFILTRATION AND TUMOR LYMPHOCYTE AND RESULTS IN CANCER PATIENTS TREATED WITH ANTI-PD-1 / PD-L1 AGENTS |
| WO2019018828A1 (en) | 2017-07-20 | 2019-01-24 | Cytomx Therapeutics, Inc. | METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF |
| KR102880156B1 (ko) | 2017-07-24 | 2025-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 항cd8 항체 및 이의 용도 |
| JP7347899B2 (ja) | 2017-08-09 | 2023-09-20 | オリオンズ バイオサイエンス インコーポレイテッド | Ｃｄ８結合物質 |
| CA3070297A1 (en) | 2017-08-11 | 2019-02-14 | Genentech, Inc. | Anti-cd8 antibodies and uses thereof |
| US11672877B2 (en) | 2017-08-23 | 2023-06-13 | Wayne State University | In vivo immunoimaging of interferon-gamma |
| CA3076611A1 (en) | 2017-09-23 | 2019-03-28 | Memorial Sloan Kettering Cancer Center | A33 antibody compositions and methods of using the same in radioimmunotherapy |
| WO2019161271A1 (en) | 2018-02-16 | 2019-08-22 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| CN112566642B (zh) | 2018-03-14 | 2025-01-17 | 纪念斯隆凯特琳癌症中心 | 抗聚唾液酸抗体及其用途 |
| AU2019351264A1 (en) | 2018-09-28 | 2021-04-29 | Imaginab, Inc. | CD8 imaging constructs and methods of use thereof |
| US20230211024A1 (en) | 2019-12-05 | 2023-07-06 | Imaginab, Inc. | Methods of imaging using multiple imaging agents |
-
2014
- 2014-03-10 CN CN202110297974.0A patent/CN113045660B/zh active Active
- 2014-03-10 KR KR1020217003074A patent/KR102353885B1/ko active Active
- 2014-03-10 EP EP21171344.1A patent/EP3889182B1/en active Active
- 2014-03-10 EP EP24169921.4A patent/EP4411378A3/en active Pending
- 2014-03-10 AU AU2014249243A patent/AU2014249243C1/en active Active
- 2014-03-10 EP EP14779573.6A patent/EP2968622B1/en active Active
- 2014-03-10 KR KR1020157028748A patent/KR20150131208A/ko not_active Ceased
- 2014-03-10 CA CA2904969A patent/CA2904969C/en active Active
- 2014-03-10 CN CN201480024657.XA patent/CN105163765A/zh active Pending
- 2014-03-10 JP JP2016501063A patent/JP6815196B2/ja active Active
- 2014-03-10 US US14/202,999 patent/US20140271462A1/en not_active Abandoned
- 2014-03-10 US US14/773,710 patent/US10414820B2/en active Active
- 2014-03-10 WO PCT/US2014/022782 patent/WO2014164553A1/en not_active Ceased
-
2016
- 2016-08-05 US US15/230,085 patent/US10377826B2/en active Active
-
2018
- 2018-12-07 JP JP2018230270A patent/JP6856611B2/ja active Active
-
2019
- 2019-04-17 AU AU2019202676A patent/AU2019202676C1/en active Active
- 2019-05-20 US US16/417,482 patent/US20190382488A1/en not_active Abandoned
- 2019-05-20 US US16/417,474 patent/US20190382487A1/en not_active Abandoned
-
2020
- 2020-01-16 US US16/745,064 patent/US12435141B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520514A5 (enExample) | ||
| IL290425A (en) | Humanized, murine or chimeric anti-cd47 monoclonal antibodies | |
| MX2017005987A (es) | Anticuerpos anti-interleucina(il)-1beta y metodos de uso. | |
| JP2018021031A5 (enExample) | ||
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| CL2018001177A1 (es) | Anticuerpos vinculados especificamente a pd-1 y sus usos. | |
| NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| PH12018500708A1 (en) | Humanized anti-human cd19 antibodies and methods of use | |
| WO2015109131A3 (en) | Bi-specific cd3 and cd19 antigen-binding constructs | |
| HK1231369A1 (zh) | 人源化或嵌合cd3抗体 | |
| WO2015010100A3 (en) | Humanized antibodies with ultralong complementarity determining regions | |
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| WO2015091853A3 (en) | Human anti-cd40 human antibodies | |
| WO2014152006A3 (en) | Anti-hepcidin antibodies and uses thereof | |
| WO2015143123A3 (en) | Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof | |
| MX2017005642A (es) | Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso. | |
| WO2015127136A3 (en) | Ebola monoclonal antibodies | |
| ZA201703510B (en) | Antibodies, uses & methods | |
| JP2015530399A5 (enExample) | ||
| NZ604464A (en) | Anti-vegf antibodies and uses thereof | |
| HRP20171964T1 (hr) | Kombinacije i njihova upotreba | |
| WO2015017146A3 (en) | Antibodies with ultralong complementarity determining regions | |
| WO2017021539A3 (en) | Novel anti-human gpvi antibodies and uses thereof | |
| JP2018515513A5 (enExample) | ||
| WO2016057683A3 (en) | Novel anti-nodal antibodies and methods of using same |